BIOTECHNOLOGY INDUSTRY NEWS

Allon Drugs Receive U.S. Patent for Treatment of Neuropathy (Nov 18)

Allon Therapeutics Reviews Product Development at BIO-Europe 2008 (Nov 17)

Amorfix Receives Third Biogen Idec Investment (Nov 17)

Update on Bioniche Phase III Clinical Trial in Bladder Cancer (Nov 17)

Patheon and Senopsys Announce Alliance (Nov 17)

InNexus Biotechnology CEO Named Business Leader of the Year (Nov 17)

Patheon and Solvias AG Announce Global Strategic Alliance to Provide Integrated Development Services (Nov 14)

Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Research at CTOS Annual Meeting (Nov 14)

YM BIOSCIENCES RESPONDS TO BBM ANNOUNCEMENT (Nov 13)

New study on males shows GARDASIL(R) reduced HPV-related diseases (Nov 13)

AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners (Nov 13)

Patheon Launches Quick To Clinic(SM) Program: Goal Is To Reduce Development Time for Customers (Nov 13)

Study uncovers overlooked risk factor that may be key to saving Canadians from first heart attacks and strokes (Nov 10)

Biovail Appoints Dr. H. Christian Fibiger Senior Vice-President, Chief Scientific Officer (Nov 6)

iCo Therapeutics Oral Amphotericin B Effective Against Visceral Leishmaniasis (Nov 6)

Cytochroma Announces Positive Comparative Data on CTA018 in Chronic Kidney Disease Model (Nov 6)

World’s First Cattle Vaccine to Reduce E. coli O157 Threat Receives Full Licensing Approval in Canada (Oct 27)
EconicheTM now available to reduce risk of food and water contamination

Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting (Oct 23)

Lignol and Suncor Sign Cellulosic Ethanol Project Development Agreement (Oct 23)

Cytochroma announces initiation of Phase II clinical trial of CTA018 for chronic kidney disease patients (Oct 23)

Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec’s Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis (Oct 23)

BELLUS Health Receives Nasdaq Deficiency Notice Relating to Market Value (Oct 15)

Angiotech's corporate partner, Boston Scientific, announces FDA approval of second-generation TAXUS(R) Liberté(R) drug-eluting stent (Oct 10)

Cardiome Provides Regulatory Update (Oct 9)

Angiotech's corporate partner, Boston Scientific, announces completion of clinical trial enrollment for third-generation drug-eluting stent (Oct 8)

Amorfix sheep scrapie results from blinded panels presented at international Prion Conference (Oct 8)

FEATURES

BIOTECanada insights magazine has a NEW LOOK! insights is our official biannual, bilingual publication to promote our members and Canada's biotechnology industry. Our largest edition yet is available online or in hard copy. Click here for a list of articles including contributions from Dr. Roberta Bondar; The Hon. Jim Prentice, Minister of Industry; and features on Canadian commercialization success, legal matters, the new face of vaccines, and how one of the biggest deals in Canadian biotech history came about between BioMS Medical Corp. and Eli Lilly.

Request your copy of insights >>>

Canada's Vaccine Industry Committee: Leadership in global health will educate readers about the value of vaccines and the role vaccines play in improving the health of Canadians.

Learn about vaccine regulation, the history of vaccine development and who today's leading innovators are. The brochure also highlights the importance of preventing flu and the benefits vaccines bring to the Canadian healthcare system.

Click here to download a copy.

To request a hard copy, email info@biotech.ca

Click here for a list of this year's Student Bursary Winners. Congratulations!

Canadian Life Sciences Industry Forecast 2007